Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NVAX
NOVAVAX, INC.
NASDAQ
$9.26
▲ UP 2.32% (0.21)

KEY STATISTICS

Market Cap$1.52 B
52w High$11.97
52w Low$6.20
Dividend Yield—
Frequency—
P/E-6.09
Volume4.20M
Shares Out.164.44M

COMPANY

LEADERSHIP

John Charles Jacobs
CHIEF EXECUTIVE
John Charles Jacobs

COMPENSATION 2026

Salary$792,917
Stock Awards$3,545,435
Incentive Plan Pay$640,331
All Other Comp.$114,040
Total$8,856,015

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 5, 1995
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
749

PRICE TARGET

Target High$25.00
Target Low$11.00
Target Median$18.00
Target Consensus$18.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$72.66M
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2019-05-10Reverse1:20

PRICE

$9.26 ▲ UP 2.32% (+$0.21)
OVERLAYS
$9.00$9.15$9.309:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM9.26

About Novavax, Inc.

https://www.novavax.com ↗

Novavax, Inc. is a biotech company developing vaccines for infectious diseases, including COVID-19, influenza, and RSV, with several candidates in advanced clinical trials and collaborations like Takeda.

INDUSTRY

Biotechnology

A PRODUCT NOVAVAX, INC. IS KNOWN FOR

Nuvaxovid™ (2025-2026 Formula)
Nuvaxovid™ (2025-2026 Formula)

Nuvaxovid is a protein-based COVID-19 vaccine using Matrix-M® adjuvant, targeting the JN.1 variant, approved for ages 12+, and is Novavax's key commercial product for COVID-19 prevention.

COMPETITORS

COMPETITOR
AZN COMPARE
BNTX COMPARE
MRNA COMPARE
PFE COMPARE
VXRT COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$13.44M $660.88M ▲$42.2M ▼—
Licensing Royalties and Other— — — $37.84M
Supply Sales$13.77M $19.61M ▲$32.64M ▲—
Nuvaxovid Sales-$332K $19.58M ▲$9.56M ▼—
Royalties and Other— — — $676K

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$56.78M $111.24M ▲$96.09M ▼$38.44M ▼
Rest of the World$13.01M $32.73M ▲$23.27M ▼$17.14M ▼
Europe$655K $3.37M ▲$20.15M ▲$1.12M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
139
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
0.61% · 8.0M
VTS.AX
0.00% · 5.2M
IWM
0.05% · 3.9M
SCHA
0.03% · 778.9K
FESM
0.10% · 734.4K
LABU
0.41% · 291.0K
EES
0.34% · 266.9K
BBP
1.25% · 164.9K
PRF
0.01% · 148.0K
XRS2.DE
0.04% · 139.5K
FSCC
0.33% · 131.5K
SILX
0.89% · 111.6K
RSSL
0.04% · 72.8K
BFOR
0.20% · 50.1K
GERM
2.50% · 20.1K
TILT
0.01% · 13.0K
RTWP.L
0.05% · 12.3K
MFUS
0.02% · 7.2K
ACSG
0.12% · 6.7K
URTY
0.02% · 6.2K
RFLR
0.06% · 5.9K
MX
MXDU
0.56% · 3.9K
VETS
0.10% · 3.8K
USFMDN.MX
0.00% · 653
AVUQ
0.00% · 529
JHMH
0.22% · 506

INSTITUTIONAL OWNERSHIP

SHARES OWNED
65.92%
HOLDERS
385
TOP 12 OF 385 · RANKED BY POSITION SIZE
Vanguard Group Inc
15.5M sh · $103.96M
Shah Capital Management
14.8M sh · $120.84M
Blackrock, Inc.
13.9M sh · $131.38M
Blackrock Inc.
11.8M sh · $149.98M
State Street Corp
11.7M sh · $110.6M
Bank Of America Corp /De/
8.3M sh · $55.71M
D. E. Shaw & Co., Inc.
7.7M sh · $62.76M
Sanofi
6.9M sh · $59.65M
Ubs Group AG
4.9M sh · $32.89M
Millennium Management LLC
4.5M sh · $30.04M
Geode Capital Management, LLC
4.2M sh · $39.64M
Two Sigma Investments, LP
4.1M sh · $38.54M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

SENATE TRADES
Pat Roberts
Pat Roberts
Sale (Full)
2020-10-13

INSIDER TRADES

★
DIRECTOR
Alton Gregg H
Purchase · 18.9K shares
2026-06-20
★
DIRECTOR
MOTT DAVID M
Purchase · 21.3K shares
2026-06-18
★
DIRECTOR
King Rachel K.
Sale · 18.9K shares
2026-06-20
★
DIRECTOR
DOUGLAS RICHARD
Purchase · 14.2K shares
2026-06-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
HOLD 1
UNDERWEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
BTIG BUY TD Cowen HOLD HC Wainwright & Co. BUY JP Morgan UNDERWEIGHT B. Riley Securities BUY

SECTORS PEERS

PEERPRICE
PGEN$6.95COMPARE
TRVI$16.79COMPARE
NKTR$72.52COMPARE
ZBIO$31.27COMPARE
NTLA$12.87COMPARE
ORIC$13.24COMPARE
WVE$5.04COMPARE
UPB$6.69COMPARE